United States Acute Myeloid Leukaemia Therapeutics Market to hit US$ 2.17 Billion by 2033 | Major Compnies 2026 - Genentech Inc., Servier Pharmaceuticals LLC, Bristol-Myers Squibb Company

Leander, Texas and Tokyo, Japan - Jan.08.2026
As per DataM intelligence research report" The global acute myeloid leukemia therapeutics market size reached US$ 2.89 Billion in 2023 with a rise of US$ 3.15 Billion in 2024 and is expected to reach US$ 7.25 Billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025-2033." Advances in targeted therapies and rising cancer prevalence are accelerating AML drug development.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/acute-myeloid-leukaemia-therapeutics-market?prasad

United States Recent Industry Developments

✅ In November 2025, The FDA approved ziftomenib (Komzifti) for relapsed/refractory AML with NPM1 mutations The approval provides a targeted oral therapy for a genetic subtype with few options It represents a breakthrough in precision medicine for blood cancer

✅ In October 2025, Syndax Pharmaceuticals received FDA approval for revumenib (Revuforj) The drug targets KMT2A-rearranged acute leukemias in both adults and children It offers the first dedicated treatment for this aggressive biological subtype

✅ In September 2025, AbbVie presented data on a new combination therapy involving Venetoclax The regimen showed improved survival rates in older patients ineligible for chemotherapy It reinforces the standard of care for the elderly AML population in the U.S.

✅ In August 2025, A U.S. biotech firm initiated a trial for a CD123-targeted antibody-drug conjugate The therapy aims to deliver potent toxins directly to leukemia cells It expands the pipeline of immunotherapies available to U.S. patients

Japan Recent Industry Developments

✅ In December 2025, Kyowa Kirin filed for PMDA approval of ziftomenib in Japan The filing follows successful bridging studies confirming safety in Japanese patients It accelerates the availability of menin inhibitors in the Asian market

✅ In November 2025, Daiichi Sankyo launched a new FLT3 inhibitor for newly diagnosed AML The drug is approved for use in combination with standard chemotherapy It improves outcomes for patients with the common FLT3 mutation in Japan

✅ In October 2025, The National Cancer Center Japan started a nationwide genomic screening project for AML The "LC-SCRUM" expansion identifies patients eligible for novel targeted therapies It promotes the adoption of personalized medicine in Japanese hematology

✅ In September 2025, Chugai Pharmaceutical received orphan drug designation for a new bispecific antibody The drug engages T-cells to attack AML blasts expressing specific antigens It offers hope for relapsed patients in Japan who have exhausted other options

acute myeloid leukaemia therapeutics Market: Drivers
The acute myeloid leukaemia therapeutics market is expanding due to rising cancer incidence and improved diagnostic capabilities. Advances in targeted therapies and precision medicine improve treatment outcomes. Growing awareness and early diagnosis drive therapeutic adoption. Regulatory approvals for novel drugs strengthen market confidence. Increasing investment in oncology research supports pipeline development. Specialized treatment centers improve patient access.

Market growth is reinforced by innovations in immunotherapy and combination treatments. Pharmaceutical companies focus on personalized treatment approaches. Emerging markets are expanding access to advanced cancer care. Clinical trials and real-world evidence support adoption. Supportive reimbursement frameworks enhance affordability. AML therapeutics remain critical in hematologic oncology care.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/acute-myeloid-leukaemia-therapeutics-market?prasad

acute myeloid leukaemia therapeutics Market: Major Players
Genentech, Inc.; Servier Pharmaceuticals LLC; Bristol-Myers Squibb Company; Rigel Pharmaceuticals, Inc.; Novartis AG; Astellas Pharma Inc., Daiichi Sankyo, Inc.; Jazz Pharmaceuticals plc; Pfizer Inc.; and Teva Pharmaceutical Industries Ltd., among others.

Segment Covered in the acute myeloid leukaemia therapeutics Market:
By Drug Class
The market is segmented into chemotherapy 40%, targeted therapy 35%, immunotherapy 15%, and others 10%. Chemotherapy continues to dominate due to its long-standing role as first-line treatment, especially in induction and consolidation therapy. However, targeted therapies are witnessing rapid growth driven by advancements in precision medicine, improved survival outcomes, and increased approvals of FLT3, IDH1, and IDH2 inhibitors. Immunotherapy adoption is expanding with ongoing clinical trials and combination therapy approaches.

By Disease Type
Based on disease type, the market includes myeloblastic leukemia 30%, myelomonocytic leukemia 25%, promyelocytic leukemia 20%, monocytic leukemia 15%, and others 10%. Myeloblastic leukemia leads due to higher incidence rates and availability of standardized treatment protocols. Promyelocytic leukemia shows strong treatment success rates, driving consistent therapeutic demand.

By Route of Administration
Route of administration segmentation comprises parenteral 70% and oral 30%. Parenteral administration dominates due to intravenous chemotherapy and biologics commonly used in hospital settings. Oral therapies are gaining traction with the introduction of targeted agents that enable outpatient treatment and improved patient compliance.

By Distribution Channel
Distribution channels include hospital pharmacies 65%, retail pharmacies 20%, and online pharmacies 15%. Hospital pharmacies dominate owing to the complex nature of AML treatment, inpatient care requirements, and administration of injectable therapies. Retail and online pharmacies are expanding with increased availability of oral targeted therapies.

Regional Analysis
North America - 35% Share
North America leads the AML therapeutics market with 35% share, driven by high disease awareness, advanced healthcare infrastructure, and strong presence of key pharmaceutical players. Early adoption of novel targeted and immunotherapies supports market growth.

Europe - 25% Share
Europe accounts for 25% share supported by strong oncology research, favorable reimbursement policies, and increasing adoption of precision medicine. Germany, France, and the UK are major contributors.

Asia Pacific - 20% Share
Asia Pacific holds 20% share with rising AML incidence, improving diagnostic capabilities, and expanding access to advanced therapies in China, Japan, and India.

Latin America - 12% Share
Latin America represents 12% share driven by gradual improvements in oncology care and increased availability of chemotherapy-based treatments in Brazil and Mexico.

Middle East & Africa - 8% Share
Middle East & Africa accounts for 8% share, supported by growing healthcare investments and expanding access to oncology treatments in select countries.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=acute-myeloid-leukaemia-therapeutics-market

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.